A Phase 1/2 study evaluating rese-cel in patients with multiple sclerosis (MS).
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs Resecabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms RESET-MS
- 17 Jan 2025 New trial record
- 13 Jan 2025 Cabaletta Bio received The Investigational New Drug (IND) application for rese-cel has been allowed to proceed within the routine 30-day window by the FDA for the RESET-MS trial,